Europe’s pharmaceutical landscape is undergoing a significant change due to its medicine shortage problem, which has a stubborn root cause: fragile upstream links. The situation becomes apparent at the pharmacy counter, but it originates much earlier, at the level of raw materials, intermediates, and APIs,... Continue reading
Return to previous page
Page 5
Introduction: Licensing as a Growth Engine in Pharma The global pharmaceutical and biotech companies are entering an era of collaboration, agility, and strategic alliances. As the R&D cost rises and regulatory timelines stretch, licensing deals have become essential levers for pharma companies to drive innovation... Continue reading
The regulatory landscape for biosimilars is shifting significantly in 2025. The FDA has taken two big steps that collectively make it faster and cheaper to bring many biosimilars to market: In June 2024, the FDA proposed to drop “switching” studies for the interchangeable designation, saying... Continue reading
The pharma industry has seen a wave of change over the decades, driven by digital innovation, data analytics & global collaboration. A major catalyst behind this change has been the rise of Global Capability Centers (GCCs), strategic hubs designed to consolidate talent, technology, and operational... Continue reading
Introduction: The pharma ecosystem is quite complex, wherein companies operate across various channels, ranging from hospital procurement networks to retail pharmacies. While this expands their market reach, it also creates challenges in forecasting demand because of fragmented data sources, channel silos, and inconsistent demand visibility.... Continue reading
Background: In the current scenario, the competitive landscape of oncology TA, where innovation moves rapidly, pharma companies face intense pressure to optimize their pipeline investments. With hundreds of potential cancers and limited resources, selecting the most promising therapeutic indications for early-stage assets is both critical... Continue reading
Background: In an evolving global disease landscape, identifying the right therapy areas or indication setting for investment is a strategic move that defines a company’s growth trajectory, especially in emerging markets where potential is enormous but super fragmented. Our biopharma client, a global player aiming... Continue reading
Background: Launching a new therapy in the oncology space is one of the most complex and challenging in the pharma and biotech industries. With evolving treatment landscapes, shifting market dynamics, and diverse patient journeys across geographies, forecasting future uptake has never been straightforward. One of... Continue reading
Introduction: In recent years, the healthcare landscape has evolved toward an evidence-based, patient-centric architecture. Although conventional clinical trials remain the gold standard, they do not always capture the full gamut of patient experience, follow-up behavior, and the long-term impact of standard-of-care practices observed in real-world... Continue reading
Introduction: In today’s competitive pharmaceutical industry, success relies on anticipating market changes. With rapidly growing data sources, AI-powered data analytics solutions, and predictive modeling, organizations are commanded to stay ahead of the competition. The Challenge: Pharma companies rely heavily on retrospective market research — analyzing... Continue reading